148 related articles for article (PubMed ID: 16764931)
1. Heteroaryl substituted titanocenes as potential anti-cancer drugs.
Sweeney N; Gallagher WM; Müller-Bunz H; Pampillón C; Strohfeldt K; Tacke M
J Inorg Biochem; 2006 Sep; 100(9):1479-86. PubMed ID: 16764931
[TBL] [Abstract][Full Text] [Related]
2. Methoxy-phenyl substituted ansa-titanocenes as potential anti-cancer drugs derived from fulvenes and titanium dichloride.
Tacke M; Cuffe LP; Gallagher WM; Lou Y; Mendoza O; Müller-Bunz H; Rehmann FJ; Sweeney N
J Inorg Biochem; 2004 Dec; 98(12):1987-94. PubMed ID: 15541486
[TBL] [Abstract][Full Text] [Related]
3. Novel achiral titanocene anti-cancer drugs synthesised from bis-N,N-dimethylamino fulvene and lithiated heterocyclic compounds.
Pampillón C; Claffey J; Hogan M; Tacke M
Biometals; 2008 Apr; 21(2):197-204. PubMed ID: 17665139
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and cytotoxicity studies of new dimethylamino-functionalised and aryl-substituted titanocene anti-cancer agents.
Pampillón C; Claffey J; Strohfeldt K; Tacke M
Eur J Med Chem; 2008 Jan; 43(1):122-8. PubMed ID: 17412456
[TBL] [Abstract][Full Text] [Related]
5. Dimethylamino-functionalised and N-heteroaryl-substituted titanocene anticancer drugs: synthesis and cytotoxicity studies.
Hickey T; Claffey J; Fitzpatrick E; Hogan M; Pampillón C; Tacke M
Invest New Drugs; 2007 Oct; 25(5):425-33. PubMed ID: 17516024
[TBL] [Abstract][Full Text] [Related]
6. Bioorganometallic fulvene-derived titanocene anti-cancer drugs.
Strohfeldt K; Tacke M
Chem Soc Rev; 2008 Jun; 37(6):1174-87. PubMed ID: 18497930
[TBL] [Abstract][Full Text] [Related]
7. Pseudo-halide derivatives of titanocene: synthesis and cytotoxicity studies.
Claffey J; Deally A; Gleeson B; Hogan M; Méndez LM; Müller-Bunz H; Patil S; Wallis D; Tacke M
Metallomics; 2009 Nov; 1(6):511-7. PubMed ID: 21305159
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and cytotoxicity studies of new morpholino-functionalised and N-heteroaryl-substituted titanocene anticancer drugs.
Hogan M; Claffey J; Pampillón C; Tacke M
Med Chem; 2008 Mar; 4(2):91-9. PubMed ID: 18336326
[TBL] [Abstract][Full Text] [Related]
9. Antitumour activity of [1,2-di(cyclopentadienyl)-1,2-di(p-N,N-dimethylaminophenyl)-ethanediyl] titanium dichloride in xenografted Ehrlich's ascites tumour.
Valadares MC; Ramos AL; Rehmann FJ; Sweeney NJ; Strohfeldt K; Tacke M; Queiroz ML
Eur J Pharmacol; 2006 Mar; 534(1-3):264-70. PubMed ID: 16513106
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological evaluation of achiral indole-substituted titanocene dichloride derivatives.
Deally A; Hackenberg F; Lally G; Tacke M
Int J Med Chem; 2012; 2012():905981. PubMed ID: 25954531
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxic studies of substituted titanocene and ansa-titanocene anticancer drugs.
Gómez-Ruiz S; Kaluderović GN; Prashar S; Polo-Cerón D; Fajardo M; Zizak Z; Sabo TJ; Juranić ZD
J Inorg Biochem; 2008 Aug; 102(8):1558-70. PubMed ID: 18353439
[TBL] [Abstract][Full Text] [Related]
12. Study of the cytotoxicity and particle action in human cancer cells of titanocene-functionalized materials with potential application against tumors.
García-Peñas A; Gómez-Ruiz S; Pérez-Quintanilla D; Paschke R; Sierra I; Prashar S; del Hierro I; Kaluđerović GN
J Inorg Biochem; 2012 Jan; 106(1):100-10. PubMed ID: 22112846
[TBL] [Abstract][Full Text] [Related]
13. Antitumour bis(cyclopentadienyl) metal complexes: titanocene and molybdocene dichloride and derivatives.
Abeysinghe PM; Harding MM
Dalton Trans; 2007 Aug; (32):3474-82. PubMed ID: 17680034
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of the cytotoxicity of titanocene dichloride by aging in organic co-solvent.
Ravera M; Cassino C; Monti E; Gariboldi M; Osella D
J Inorg Biochem; 2005 Dec; 99(12):2264-9. PubMed ID: 16209887
[TBL] [Abstract][Full Text] [Related]
15. A new generation of anticancer drugs: mesoporous materials modified with titanocene complexes.
Pérez-Quintanilla D; Gómez-Ruiz S; Zizak Z; Sierra I; Prashar S; del Hierro I; Fajardo M; Juranić ZD; Kaluderović GN
Chemistry; 2009; 15(22):5588-97. PubMed ID: 19370742
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, characterization, cytotoxicity, and hydrolytic behavior of C2- and C1-symmetrical Ti(IV) complexes of tetradentate diamine bis(phenolato) ligands: a new class of antitumor agents.
Peri D; Meker S; Shavit M; Tshuva EY
Chemistry; 2009; 15(10):2403-15. PubMed ID: 19156656
[TBL] [Abstract][Full Text] [Related]
17. In-vitro anti-tumor activity studies of bridged and unbridged benzyl-substituted titanocenes.
Kelter G; Sweeney NJ; Strohfeldt K; Fiebig HH; Tacke M
Anticancer Drugs; 2005 Nov; 16(10):1091-8. PubMed ID: 16222151
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and cytotoxicity studies of titanocene C analogues.
Hogan M; Claffey J; Fitzpatrick E; Hickey T; Pampillón C; Tacke M
Met Based Drugs; 2008; 2008():754358. PubMed ID: 18274663
[TBL] [Abstract][Full Text] [Related]
19. Analyses of Titanocenes in the spheroid-based cellular angiogenesis assay.
Weber H; Claffey J; Hogan M; Pampillón C; Tacke M
Toxicol In Vitro; 2008 Mar; 22(2):531-4. PubMed ID: 17981007
[TBL] [Abstract][Full Text] [Related]
20. Imidazolin-2-iminato titanium complexes: synthesis, structure and use in ethylene polymerization catalysis.
Tamm M; Randoll S; Herdtweck E; Kleigrewe N; Kehr G; Erker G; Rieger B
Dalton Trans; 2006 Jan; (3):459-67. PubMed ID: 16395445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]